Modifications in Cardiovascular Risk Factors When Performing Physical Exercise in Hypertensive and Dyslipidemic Patients
NCT ID: NCT04832048
Last Updated: 2021-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2016-09-20
2019-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Effect of Individual Variants of Agonist-antagonist and Traditional Agonistic Resistance Training on Cardiovascular Parameters
NCT06047678
Factors and Prognostic Significance of Impaired Exercise Tolerance in Women Over 40 With Arterial Hypertension
NCT04802369
Effectiveness of Non-pharmacological Interventions in Patients With Cardiovascular Risk Factors in Primary Care
NCT03452709
Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects
NCT02670681
Aerobic Exercise and Resistant Hypertension
NCT05563077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants in the HIT and LMIT groups followed the same physical training program, with the only difference being the intensity of the training. The program included two phases of physical exercise lasting 12 weeks and 16 weeks, respectively, separated by a 7-week rest period, which coincided with a holiday period. The times of both phases were not equal in terms of duration, since it is a community physical exercise program established by the Region of Murcia, and does not depend on the researchers.
The program was developed by graduates in Physical Activity and Sport Sciences, who were in charge of teaching the exercises and supervised each training session.
Participants assigned to the HIT and LMIT groups were given guidelines to continue physical exercise during the 7-week rest period, while participants in the control group were offered to participate in the program after the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High intensity training (HIT) group
The HIT group performed the exercises with loads at 80-90% of HRF.
Therapeutic physical exercise
The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.
Intensity was be determined by Maximum Heart Rate (HRF).
Low-moderate intensity training (LMIT) group
The HIT group performed the exercises with the loads at 50-70% of the HRF
Therapeutic physical exercise
The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.
Intensity was be determined by Maximum Heart Rate (HRF).
No training group
They did not perform any type of programmed physical exercise during the study.
No physical exercise
No programmed physical exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Therapeutic physical exercise
The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.
Intensity was be determined by Maximum Heart Rate (HRF).
No physical exercise
No programmed physical exercise
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Under treatment with at least one antihypertensive drug for hypertension. Treatment should have lasted at least 12 months prior to inclusion in the study.
* Diagnosed with dyslipidemia under pharmacological treatment or with a specific hypercholesterolemia (\> 200 mg/dL) in the past and a cholesterol level at the start of the study greater than 200 mg/dL.
* Patient in Primary Prevention.
* Subjects who do not develop physical exercise scheduled on a weekly basis.
* Subjects who have given written informed consent to participate in the study.
Exclusion Criteria
* Diagnosis of ischemic and/or cerebrovascular heart disease.
* Presence of chronic diseases that prevent the performance of a physical exercise program or a stress test (disabling arthropathies, chronic moderate/severe pneumopathies, arrhythmias, etc).
* Severe mental illnesses: psychosis, severe depressive disorder, neurosis.
* Diabetes mellitus.
* Presence of absolute or relative contraindications dictated by the American College of Sports Medicine (ACSM, 1995), during the performance of the stress tests.
* Pregnant or breast-feeding women
* Inability to understand the informed consent.
40 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Católica San Antonio de Murcia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Francisco Javier López Román
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic University of Murcia
Murcia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCAMCFE-00021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.